Cancer
Conditions
Brief summary
Anti-tumor activity, as assessed by objective response at 16 weeks, Stable disease at 16 weeks, Treatment-related and serious adverse events
Detailed description
Duration of response, progression-free and overall survival, Duration of treatment on study (time on drug), Percentage of patients that are treated based on their molecular tumor profile, Description of concordance between mutational profile of pre-treatment tumor biopsies and mutational profile according to tumor profiling tests that were used to enroll patients, Identification of patterns of resistance based on serial tumor biopsies and liquid biopsies
Interventions
DRUGInlyta 7 mg film-coated tablets
DRUGLynparza 150 mg film-coated tablets
DRUGPerjeta 420 mg concentrate for solution for infusion
DRUGTecentriq 1 200 mg concentrate for solution for infusion
DRUGLynparza 100 mg film-coated tablets
DRUGHerceptin 150 mg powder for concentrate for solution for infusion
Sponsors
Rigshospitalet
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anti-tumor activity, as assessed by objective response at 16 weeks, Stable disease at 16 weeks, Treatment-related and serious adverse events | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of response, progression-free and overall survival, Duration of treatment on study (time on drug), Percentage of patients that are treated based on their molecular tumor profile, Description of concordance between mutational profile of pre-treatment tumor biopsies and mutational profile according to tumor profiling tests that were used to enroll patients, Identification of patterns of resistance based on serial tumor biopsies and liquid biopsies | — |
Countries
Denmark
Outcome results
None listed